Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Gets Price Target Reduction from Royal Bank Of Canada

Eyepoint Pharmaceuticals (NASDAQ:EYPT) had its price objective decreased by analysts at Royal Bank Of Canada to $1.00 in a note issued to investors on Tuesday, Benzinga reports. The firm currently has a “sector perform” rating on the stock. Royal Bank Of Canada’s target price suggests a potential upside of 115.98% from the company’s current price.

EYPT has been the topic of several other research reports. HC Wainwright reiterated a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research note on Tuesday. Jefferies Financial Group lowered shares of Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating and set a $1.00 price objective on the stock. in a research note on Monday. Stifel Nicolaus began coverage on shares of Eyepoint Pharmaceuticals in a research note on Thursday, July 16th. They set a “buy” rating and a $40.00 price objective on the stock. Wall Street Zen upgraded shares of Eyepoint Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday, September 27th. Finally, Citigroup dropped their price objective on shares of Eyepoint Pharmaceuticals to $17.00 and set a “buy” rating on the stock in a research note on Tuesday, August 18th. Two research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $21.85.

Eyepoint Pharmaceuticals Stock Performance

Shares of EYPT stock traded up $0.02 during trading hours on Tuesday, hitting $0.46. 18,967,239 shares of the company were exchanged, compared to its average volume of 3,130,446. Eyepoint Pharmaceuticals has a one year low of $0.40 and a one year high of $19.11. The business’s 50-day simple moving average is $4.77 and its two-hundred day simple moving average is $10.30. The stock has a market capitalization of $39.92 million, a price-to-earnings ratio of -0.12 and a beta of 1.67.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%. The company had revenue of $0.51 million for the quarter, compared to the consensus estimate of $0.45 million. As a group, analysts anticipate that Eyepoint Pharmaceuticals will post -3.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Cyndeo Wealth Partners LLC boosted its holdings in shares of Eyepoint Pharmaceuticals by 46.8% in the third quarter. Cyndeo Wealth Partners LLC now owns 35,519 shares of the company’s stock valued at $116,000 after acquiring an additional 11,329 shares in the last quarter. Engineers Gate Manager LP bought a new position in shares of Eyepoint Pharmaceuticals in the second quarter valued at approximately $161,000. Integrated Wealth Concepts LLC bought a new position in shares of Eyepoint Pharmaceuticals in the second quarter valued at approximately $72,000. Squarepoint Ops LLC boosted its holdings in shares of Eyepoint Pharmaceuticals by 22.3% in the second quarter. Squarepoint Ops LLC now owns 98,002 shares of the company’s stock valued at $1,401,000 after acquiring an additional 17,883 shares in the last quarter. Finally, Baird Financial Group Inc. boosted its holdings in shares of Eyepoint Pharmaceuticals by 16.4% in the second quarter. Baird Financial Group Inc. now owns 32,732 shares of the company’s stock valued at $468,000 after acquiring an additional 4,613 shares in the last quarter. 99.41% of the stock is currently owned by institutional investors.

Eyepoint Pharmaceuticals News Roundup

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: Royal Bank of Canada set a $1.00 price target, implying substantial potential upside from recent levels, while assigning a “sector perform” rating. However, the target was lowered, limiting the bullish significance. Tickerreport analyst update
• Neutral Sentiment: Mizuho reaffirmed its “neutral” rating and set a $0.50 price target, only modestly above the recent share price. HC Wainwright also reaffirmed its “neutral” rating. Tickerreport analyst update
• Neutral Sentiment: Unusual options activity saw investors purchase 7,885 call options, 69% above typical daily volume. This may indicate speculative interest but does not confirm a fundamental recovery.
• Negative Sentiment: EyePoint reported disappointing topline results from the LUCIA Phase 3 trial of DURAVYU in wet AMD. Shares have lost nearly 80% following the results, severely damaging confidence in the company’s lead program. LUCIA trial results
• Negative Sentiment: EyePoint plans to cut 53% of its workforce and halt wet-AMD clinical trials early, redirecting resources toward DURAVYU development in diabetic macular edema. The move should reduce expenses but highlights the scale of the clinical setback. EyePoint strategic prioritization
• Negative Sentiment: Guggenheim downgraded EYPT to “neutral,” while Jefferies cut its rating from “buy” to “hold” and set a $1.00 target. JPMorgan reaffirmed an “underweight” rating, reinforcing cautious analyst sentiment.
• Negative Sentiment: Levi & Korsinsky announced an investigation into potential securities-law violations related to the LUCIA results, adding legal and reputational risk for shareholders. EyePoint investigation notice

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for serious eye diseases. The company specializes in sustained-release drug delivery technologies designed to provide extended treatment in the eye and potentially reduce the frequency of injections or other interventions.

EyePoint’s commercial products include YUTIQ, an intravitreal implant that delivers fluocinolone acetonide for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, an intraocular suspension of dexamethasone used to treat postoperative inflammation following ocular surgery.